Lavelle Kristen, Chamberlain Chester, German Michael, Anderson Mark, Nip Angel, Gitelman Stephen E
Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA 94143, USA.
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143, USA.
JCEM Case Rep. 2024 May 3;2(5):luae065. doi: 10.1210/jcemcr/luae065. eCollection 2024 May.
We report the first case of imatinib use in an adolescent with diabetes and suggest that it impacts the natural course of disease. A 14-year-old male patient presented in diabetic ketoacidosis (DKA) and was diagnosed with presumed autoantibody-negative type 1 diabetes (T1D) as well as myeloid neoplasm with platelet-derived growth factor receptor beta (PDGFRB) rearrangement. After starting exogenous insulin and imatinib, he experienced a 1.7-point reduction in glycated hemoglobin (HbA1c) and a 71% reduction in insulin requirement with sustained partial diabetes remission. Our case suggests imatinib as a potential therapeutic agent for pediatric T1D.
我们报告了首例在患有糖尿病的青少年中使用伊马替尼的病例，并表明它会影响疾病的自然进程。一名14岁男性患者出现糖尿病酮症酸中毒（DKA），被诊断为疑似自身抗体阴性的1型糖尿病（T1D）以及伴有血小板衍生生长因子受体β（PDGFRB）重排的髓系肿瘤。在开始使用外源性胰岛素和伊马替尼后，他的糖化血红蛋白（HbA1c）降低了1.7个百分点，胰岛素需求量减少了71%，糖尿病持续部分缓解。我们的病例表明伊马替尼可能是治疗儿童T1D的一种药物。
